BME100 f2013:W900 Group2 L2

From OpenWetWare
Jump to navigationJump to search
BME 100 Fall 2013 Home
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help


Name: Robert Rye
Name: John Richards
Name: Vivian Vuong
Name: Steven Nye
Name: Leo Santos


Descriptive Statistics

Experiment 1

Experiment 1 analyzes how different dosages affect inflammotin levels in rats and humans.

Experiment 2


Experiment 1

Experiment 2

  • The 68-72 age group did not have a patient in this dosage category

(Please include well-labeled graphs of the results.)


Experiment 1
ANOVA test on how LPS dosage affects humans' inflammotin levels

  • The desriptive data on rats including an unsignificant T Test value.

Experiment 2


Generally, inflammotin levels increase with increase LPS dosage.

The different doses of LPS on rats is insignificant based on the T Test of the data observed from the 0 mg and 5 mg doses. The T Test value of 0.87 is much higher than the value of .05 which indicates that the value is insignificant (.087 > .05).

In contrast, the differences of inflammotin levels in humans when given different doses are significant. This is seen in the ANOVA Test and the LPS Dosage Effect on Inflammotin Level graph. On the ANOVA Test, the p value was less than 0.5, which means that LPS has a great impact on the inflammotin levels in humans. On the graph, an * on a line indicates that there is a significant difference between two of the doses. This was determined by running multiple t-tests and using the Bonferroni Correction Test where the p-value was corrected to 0.5/4 (0.0083). Since all six comparisons had a p-value less than 0.0083 then that means there is a significant difference among all six. Standard deviation describes the variability of the data within each dosage group.The lowest standard deviation was among the 0mg dosage group because people started out with similar inflammotin levels. However, the standard deviation was the highest within the 15mg group. LPS dosage does not affect everyone's inflammotin levels the same because there are other factors that play a role in how people react to LPS (age, race, genes, etc.).

Age is one of the factors that influence the effects of LPS. When looking at the 0mg bar graph comparing different age groups, inflammotin levels seemed to increase with age. In addition, the 5 and 15mg dosage seemed to have a greater effect on inflammotin levels as age increased.

(Please discuss the results and statistical analysis from both experiments. State your conclusion.)